SNY

Sanofi ADR New York Stock Exchange
$53.9
Open: $52.27 High: $52.74 Low: $52.02 Close: $52.08
Range: 2021-06-23 - 2021-06-24
Volume: 1,265,859
Market: Closed
Powered by Finage Stock APIDelayed data
SNY
Sanofi ADR 54, Rue La Boétie Paris , 75008 http://www.sanofi.com
Sanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.
  • CEO: Olivier Brandicourt
  • Employees: 106,566
  • Sector: Healthcare
  • Industry: Drug Manufacturers
SNY News
Latest news about the SNY
  • ‘Vaccination is very effective against the Delta variant’: Doctor

    Dr. Shereef Elnahal, University Hospital CEO and former NJDOH Commissioner, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

    View More →
  • Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

    Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

    View More →
  • Covid-19 Showed mRNA Vaccines Work. Translate Bio, Sanofi, Are Testing One for Flu.

    The world has settled for flu vaccines that are no more than 50% effective, so a better product could reshape the market, and perhaps expand it.

    View More →
  • Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

    Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate. The trial will evaluate several dose levels of both vaccine formulations given to healthy adults 18 - 49 years of age. Interim data from the trial is

    View More →
  • Delta COVID-19 variant likely to become dominant U.S. strain: Doctor

    Dr. Susannah Hills, Pediatric Airway surgeon and assistant professor of ENT at Columbia University Medical Center, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

    View More →
  • Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients

    The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.

    View More →
  • How This Pharma Company Can Benefit From Its Competitors

    The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.

    View More →
  • Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis

    The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. Aubagio was initially approved in the European Union in 2013 for the treatment of adult patients with RRMS, and the European Commission's approval for the pediatric indication provides an additional year of marketing protection in th

    View More →
  • Gov. Ducey’s decision to block COVID-19 policies for universities is ‘not based in science’: Doctor

    Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss to discuss the latest on the coronavirus pandemic.

    View More →
  • European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

    European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis PARIS – June 18, 2021 - The European Commission (EC) has approved Aubagio® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. The approval confirms Aubagio as the first

    View More →
  • The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health

    The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health

    View More →
  • Affordable Care Act survives third Supreme Court challenge

    Andy Slavitt, former White House COVID-19 Response Team adviser, author of ‘PREVENTABLE: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response’, joins Yahoo Finance to discuss the COVID-19 response in the U.S. and the Supreme court upholding the Affordable Care Act.

    View More →
  • Top Stock Reports for Apple, Home Depot & Sanofi

    Top Stock Reports for Apple, Home Depot & Sanofi

    View More →
  • Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

    View More →
  • Where Do Hedge Funds Stand On Caterpillar Inc. (CAT)?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 866 world-class investment firms that we track and now have access to the collective wisdom contained in […]

    View More →
  • COVID-19 pandemic is ‘far from over in other parts of the world’: Doctor

    Dr. Gustavo Ferrer, President of Aventura Pulmonary Institute, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.

    View More →
  • RAPT Reports Positive Data From Atopic Dermatitis Study

    RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

    View More →
  • FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

    View More →
  • Workers sue over mandatory COVID-19 vaccination

    Yahoo Finance’s Alexis Keenan reports the latest on vaccination mandates and bans on vaccination proof.

    View More →
  • Top Pharmaceutical Stocks for Q3 2021

    These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2021.

    View More →